z-logo
open-access-imgOpen Access
Development of universal antidotes to control aptamer activity
Author(s) -
Sabah Oney,
Ruby T. S. Lam,
Kristin M. Bompiani,
Charlene M. Blake,
George Quick,
Jeremy D. Heidel,
Joanna Yi-Ching Liu,
Brendan Mack,
Mark E. Davis,
Kam W. Leong,
Bruce A. Sullenger
Publication year - 2009
Publication title -
nature medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.536
H-Index - 547
eISSN - 1546-170X
pISSN - 1078-8956
DOI - 10.1038/nm.1990
Subject(s) - aptamer , antidote , oligonucleotide , pharmacology , computational biology , chemistry , medicine , biology , biochemistry , toxicity , genetics , organic chemistry , dna
With an ever increasing number of people taking numerous medications, the need to safely administer drugs and limit unintended side effects has never been greater. Antidote control remains the most direct means to counteract acute side effects of drugs, but, unfortunately, it has been challenging and cost prohibitive to generate antidotes for most therapeutic agents. Here we describe the development of a set of antidote molecules that are capable of counteracting the effects of an entire class of therapeutic agents based upon aptamers. These universal antidotes exploit the fact that, when systemically administered, aptamers are the only free extracellular oligonucleotides found in circulation. We show that protein- and polymer-based molecules that capture oligonucleotides can reverse the activity of several aptamers in vitro and counteract aptamer activity in vivo. The availability of universal antidotes to control the activity of any aptamer suggests that aptamers may be a particularly safe class of therapeutics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom